[HTML][HTML] Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory …
B Ghanem - Investigational New Drugs, 2023 - Springer
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are chimeric antigen
receptor (CAR) T-cell therapies used to treat adult patients with relapsed or refractory …
receptor (CAR) T-cell therapies used to treat adult patients with relapsed or refractory …
P1111: comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel in relapsed/refractory follicular lymphoma
M Dickinson, J Martinez-Lopez, E Jousseaume… - …, 2022 - journals.lww.com
Background: The chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-
cel) and axicabtagene ciloleucel (axi-cel) have demonstrated clinical benefits in treating …
cel) and axicabtagene ciloleucel (axi-cel) have demonstrated clinical benefits in treating …
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
M Dickinson, J Martinez-Lopez… - Leukemia & …, 2024 - Taylor & Francis
Regulatory approvals of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel)
have established the feasibility of chimeric antigen receptor T-cell therapies for the treatment …
have established the feasibility of chimeric antigen receptor T-cell therapies for the treatment …
Axicabtagene ciloleucel in the management of follicular lymphoma: current perspectives on clinical utility, patient selection and reported outcomes
R Mohty, MA Kharfan-Dabaja… - Cancer Management and …, 2023 - Taylor & Francis
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor T-
cell therapy (CAR-T) that has shown efficacy in B-cell non-Hodgkin's lymphoma. It has …
cell therapy (CAR-T) that has shown efficacy in B-cell non-Hodgkin's lymphoma. It has …
Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL).
C Jacobson, MT Hemmer, Z Hu… - Hematological …, 2023 - search.ebscohost.com
Encore Abstract-previously submitted to ASCO 2023 and EHA 2023 The research was
funded by: The research was funded by: Kite, a Gilead Company. The following pts were …
funded by: The research was funded by: Kite, a Gilead Company. The following pts were …
[HTML][HTML] Assessment of healthcare resource utilization and costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with …
NH Fowler, M Dickinson, M Ghosh, A Chen… - Blood, 2021 - Elsevier
Background: Follicular lymphoma (FL) is the second most frequently diagnosed Non-
Hodgkin lymphoma subtype in Western countries. Patients often undergo multiple lines of …
Hodgkin lymphoma subtype in Western countries. Patients often undergo multiple lines of …
S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
C Jacobson, MT Hemmer, ZH Hu, M Frank… - …, 2023 - journals.lww.com
Background: Axicabtagene ciloleucel (axi-cel) is an autologous chimeric antigen receptor
(CAR) T-cell therapy approved for adult patients with relapsed or refractory (R/R) follicular …
(CAR) T-cell therapy approved for adult patients with relapsed or refractory (R/R) follicular …
[HTML][HTML] Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma
Background Axicabtagene ciloleucel (axi-cel) was the first chimeric antigen receptor (CAR)
T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) patients, while …
T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) patients, while …
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
SS Neelapu, JC Chavez, AR Sehgal, N Epperla… - Blood, 2024 - ashpublications.org
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor
(CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) …
(CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) …
Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States
OO Oluwole, MD Ray, KL Rosettie, G Ball, J Jacob… - Value in Health, 2024 - Elsevier
Objectives The results of a recent single-arm trial (ZUMA-5) of axicabtagene ciloleucel (axi-
cel) for relapsed/refractory (r/r) follicular lymphoma (FL) demonstrated high rates of durable …
cel) for relapsed/refractory (r/r) follicular lymphoma (FL) demonstrated high rates of durable …
相关搜索
- follicular lymphoma axicabtagene ciloleucel
- safety of tisagenlecleucel axicabtagene ciloleucel
- follicular lymphoma safety of tisagenlecleucel
- early outcomes axicabtagene ciloleucel
- follicular lymphoma early outcomes
- tisagenlecleucel car cost minimization
- follicular lymphoma cost minimization
- follicular lymphoma cell therapy
- cost minimization axicabtagene ciloleucel
- costs in patients cell therapy
- zuma 5 axicabtagene ciloleucel
- clinical utility axicabtagene ciloleucel
- follicular lymphoma clinical utility
- indirect comparisons axicabtagene ciloleucel
- follicular lymphoma indirect comparisons
- tisagenlecleucel car axicabtagene ciloleucel